secwatch / observer

8-K filed January 13, 2025, 6:59 PM ET ticker SYRE CIK 0001636282

other material confidence high sentiment positive materiality 0.75

Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028

Spyre Therapeutics, Inc.

Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.
Phase 1 interim data for SPY002 (TL1A) expected 2Q2025; SPY003 (IL-23) Phase 1 interim data in 2H2025.
Phase 2 platform trial in UC launching mid-2025 with SPY001, SPY002, SPY003, and combinations; initial open-label data mid-2026.
SPY002 expansion into rheumatoid arthritis; Phase 2 RA trial start mid-2025 with topline results in 2026.
SPY001 Phase 1 data showed half-life >90 days, supporting quarterly to twice-annual subcutaneous dosing.

item 2.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-005015
form_type: 8-K
ticker: SYRE
cik: 0001636282
company_name: Spyre Therapeutics, Inc.
filed_at: 2025-01-13T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.261640+00:00
generated_at: 2026-05-28T03:26:59.513478+00:00
sec_items: ["2.02", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-005015
json_url: https://secwatch.observer/filing/0001193125-25-005015.json
markdown_url: https://secwatch.observer/filing/0001193125-25-005015.md
text_url: https://secwatch.observer/filing/0001193125-25-005015.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/0001193125-25-005015-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

UFPI

UFP Industries authorizes $300M share repurchase program, replacing prior authorization

UFP INDUSTRIES INC June 1, 2026, 8:17 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VRNO

Verano Announces 1-for-5 Reverse Stock Split, Reducing Shares to ~72.9M, to Facilitate U.S. Exchange Listing

Verano Holdings Corp. June 1, 2026, 7:15 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-005015

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.